Eli Lilly and Company (NYSE:LLY) Shares Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,111 shares of the company's stock after buying an additional 1,332 shares during the quarter. Vestmark Advisory Solutions Inc.'s holdings in Eli Lilly and Company were worth $9,350,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Barn Wealth LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth $381,000. Bellevue Asset Management LLC grew its position in shares of Eli Lilly and Company by 183.5% during the fourth quarter. Bellevue Asset Management LLC now owns 567 shares of the company's stock worth $438,000 after buying an additional 367 shares in the last quarter. Freestone Capital Holdings LLC increased its stake in shares of Eli Lilly and Company by 3.2% in the fourth quarter. Freestone Capital Holdings LLC now owns 27,609 shares of the company's stock worth $21,315,000 after buying an additional 855 shares during the last quarter. Ethos Financial Group LLC raised its holdings in Eli Lilly and Company by 66.5% in the fourth quarter. Ethos Financial Group LLC now owns 1,662 shares of the company's stock valued at $1,285,000 after acquiring an additional 664 shares in the last quarter. Finally, Carmel Capital Partners LLC raised its holdings in Eli Lilly and Company by 3.3% in the fourth quarter. Carmel Capital Partners LLC now owns 629 shares of the company's stock valued at $486,000 after acquiring an additional 20 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 2.1 %

Shares of LLY stock opened at $930.12 on Thursday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The firm has a market capitalization of $881.91 billion, a PE ratio of 79.43, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. The stock has a fifty day moving average of $822.55 and a two-hundred day moving average of $848.61. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company's dividend payout ratio (DPR) is 51.24%.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Truist Financial lifted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Bank of America reiterated a "buy" rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,007.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.